{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:15:12Z","timestamp":1791890112299,"version":"4.3.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T00:00:00Z","timestamp":1530489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,29]]},"DOI":"10.1093\/ibd\/izy160","type":"journal-article","created":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T12:38:13Z","timestamp":1530535093000},"page":"2494-2500","source":"Crossref","is-referenced-by-count":158,"title":["Outcomes of Pregnancies With Maternal\/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis"],"prefix":"10.1093","volume":"24","author":[{"given":"Uma","family":"Mahadevan","sequence":"first","affiliation":[{"name":"University of California, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marla C","family":"Dubinsky","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinyu","family":"Su","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nervin","family":"Lawendy","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas V","family":"Jones","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Marren","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Graham","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan E B","family":"Clowse","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R","family":"Feldman","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C","family":"Baumgart","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Charit\u00e9 Medical Center Virchow Hospital, and Medical School of the Humboldt University of Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,7,2]]},"reference":[{"key":"key\n\t\t\t\t2018112902050457000_CIT0001","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gut.2006.108324","article-title":"A meta-analysis on the influence of inflammatory bowel disease on pregnancy","volume":"56","author":"Cornish","year":"2007","journal-title":"Gut"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0002","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/ibd.21369","article-title":"Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden","volume":"17","author":"Stephansson","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0003","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/ajg.2016.254","article-title":"The effects of active IBD during pregnancy in the era of novel IBD therapies","volume":"111","author":"de Lima-Karagiannis","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0004","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.crohns.2010.07.004","article-title":"European evidenced-based consensus on reproduction in inflammatory bowel disease","volume":"4","author":"van der Woude","year":"2010","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0005","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2015.12.003","article-title":"The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy","volume":"150","author":"Nguyen","year":"2016","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0006","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","article-title":"Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease","volume":"11","author":"Mahadevan","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0007","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.gastro.2016.04.002","article-title":"Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection","volume":"151","author":"Julsgaard","year":"2016","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0008","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0009","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0010","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0011","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study","volume":"65","author":"van der Heijde","year":"2013","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0012","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0013","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0014","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0015","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0016","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/bjd.13551","article-title":"Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial","volume":"172","author":"Bissonnette","year":"2015","journal-title":"Br J Dermatol"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0017","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0018","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0019","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0020","volume-title":"Xeljanz prescribing information","author":"Pfizer Inc"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0021","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40264-016-0431-z","article-title":"Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis","volume":"39","author":"Clowse","year":"2016","journal-title":"Drug Saf"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0022","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0023","author":"Organization of Teratology Information Specialists (OTIS) registry","year":"2017"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0024","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1148\/radiology.181.1.1887021","article-title":"In utero analysis of fetal growth: a sonographic weight standard","volume":"181","author":"Hadlock","year":"1991","journal-title":"Radiology"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0025","first-page":"1","article-title":"Update on overall prevalence of major birth defects\u2014Atlanta, Georgia, 1978\u2013","volume":"57","author":"Centers for Disease Control and Prevention (CDC)","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0026","volume-title":"Frequently Asked Questions. Early Pregnancy Loss","author":"The American College of Obstetricians and Gynecologists","year":"2015"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0027","volume-title":"NICE clinical guideline: ectopic pregnancy and miscarriage: diagnosis and initial management in early pregnancy of ectopic pregnancy and miscarriage","author":"Royal College of Obstetricians and Gynaecologists"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0028","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1136\/bmj.320.7251.1708","article-title":"Maternal age and fetal loss: population based register linkage study","volume":"320","author":"Nybo Andersen","year":"2000","journal-title":"BMJ"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0029","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0015-0282(02)04694-0","article-title":"Conception, early pregnancy loss, and time to clinical pregnancy: a population-based prospective study","volume":"79","author":"Wang","year":"2003","journal-title":"Fertil Steril"},{"key":"key\n\t\t\t\t2018112902050457000_CIT0030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1590\/S0100-72032010000300002","article-title":"Abortion in Brazil: a demographic approach","volume":"32","author":"Cecatti","year":"2010","journal-title":"Rev Bras Ginecol Obstet"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/24\/12\/2494\/26864036\/izy160.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,20]],"date-time":"2019-10-20T03:40:01Z","timestamp":1571542801000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/24\/12\/2494\/5047917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,2]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,7,2]]},"published-print":{"date-parts":[[2018,11,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izy160","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,12]]},"published":{"date-parts":[[2018,7,2]]}}}